Boyd Launches Rack Emulator to Validate Liquid Cooling System Performance for AI Infrastructure
27.8.2025 14:05:00 CEST | Business Wire | Press release
Boyd Enables Faster Testing and Validation of Direct-to-Chip Liquid Cooling Loops, Coolant Distribution Units, and Facility Cooling Systems with Boyd’s Rack Emulator
Boyd, whose chip-to-ambient liquid cooling technologies make it easier for data center owners and operators to implement new AI infrastructure, announced it launched a new thermal testing tool to help end clients more safely and efficiently deploy liquid cooled data centers and improve time to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827491684/en/
Boyd's new Rack Emulator validates liquid cooling system performance in AI data centers, helping clients more safely and efficiently deploy liquid cooled data centers with improved speed of deployment. Boyd's Rack Emulator simulates the pressure drop and heat dissipation of a rack and uses automation to test coolant distribution units (CDUs) and facility cooling systems to validate thermal performance before connecting to data center IT equipment, ensuring efficient and safe operation through start up without damage.
Boyd’s Rack Emulator simulates the pressure drop and heat dissipation of a rack and uses automation to test coolant distribution units (CDUs) and facility cooling systems to validate thermal performance before connecting to data center IT equipment, ensuring efficient and safe operation through start up without damage. The Rack Emulator is programmable and flexible to simulate any rack. Connect to the liquid cooling system and input capacity and pressure drop protocols, and Boyd’s Rack Emulator operates like a rack, simulating rack operating characteristics. The Rack Emulator can additionally test electrical inputs to the rack before the server is put in place. It is easy to operate without specialized training, making it easy to deploy at scale in data centers. Functioning as a thermal load bank and simulator packaged in a rack size, the Rack Emulator conveniently fits within a data center row minimizing the space required to do load bank testing and simplifying simulations. It is easy to ship, store, and handle, contributing to overall lower total cost of ownership. Boyd’s Rack Emulator is available to order now and will start shipping in September.
“Boyd’s new Rack Emulator will help our end clients reliably and safely validate thermal performance and safeguard their IT equipment,” said David Huang, Boyd President, Thermal Solutions Division. “We wanted to make it easy to operate so our customers can efficiently deploy at scale, accelerating their data center builds.”
Boyd’s liquid cooling technologies and global service model enable end clients to meet thermal performance specifications in an easy-to-adopt modular design. All of Boyd’s thermal technologies are backed by a heritage of high quality, reliable performance earned through decades of liquid cooling design and manufacturing excellence.
About Boyd
Boyd is the trusted global innovator of sustainable solutions that make our customers’ products better, safer, faster, and more reliable. Our innovative engineered materials and thermal solutions advance our customers’ technology to maximize performance in the world’s most advanced data centers; enhance reliability and extend range for electric and autonomous vehicles; advance the accuracy of cutting-edge personal healthcare and diagnostic systems; enable performance-critical aircraft and security technologies; and accelerate innovation in next-generation electronics and human-machine-interface. Core to Boyd’s global manufacturing is a deep commitment to protecting the environment with sustainable, scalable, lean, strategically located regional operations that reduce waste and minimize carbon footprint. We empower our employees, develop their potential, and inspire them to do the right things with integrity and accountability to champion our customers’ success.
Visit us atwww.boydcorp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250827491684/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom